Your browser doesn't support javascript.
loading
Persistence of spike-specific immune responses in BNT162b2-vaccinated donors and generation of rapid ex-vivo T cells expansion protocol for adoptive immunotherapy: A pilot study.
Mestiri, Sarra; Merhi, Maysaloun; Inchakalody, Varghese P; Taib, Nassiba; Smatti, Maria K; Ahmad, Fareed; Raza, Afsheen; Ali, Fatma H; Hydrose, Shereena; Fernandes, Queenie; Ansari, Abdul W; Sahir, Fairooz; Al-Zaidan, Lobna; Jalis, Munir; Ghoul, Mokhtar; Allahverdi, Niloofar; Al Homsi, Mohammed U; Uddin, Shahab; Jeremijenko, Andrew Martin; Nimir, Mai; Abu-Raddad, Laith J; Abid, Fatma Ben; Zaqout, Ahmed; Alfheid, Sameer R; Saqr, Hassan Mohamed Hassan; Omrani, Ali S; Hssain, Ali Ait; Al Maslamani, Muna; Yassine, Hadi M; Dermime, Said.
Afiliación
  • Mestiri S; Translational Cancer Research Facility, National Center for Cancer Care and Research/ Translational Research Institute, Hamad Medical Corporation, Doha, Qatar.
  • Merhi M; National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.
  • Inchakalody VP; Translational Cancer Research Facility, National Center for Cancer Care and Research/ Translational Research Institute, Hamad Medical Corporation, Doha, Qatar.
  • Taib N; National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.
  • Smatti MK; Translational Cancer Research Facility, National Center for Cancer Care and Research/ Translational Research Institute, Hamad Medical Corporation, Doha, Qatar.
  • Ahmad F; National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.
  • Raza A; Translational Cancer Research Facility, National Center for Cancer Care and Research/ Translational Research Institute, Hamad Medical Corporation, Doha, Qatar.
  • Ali FH; National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.
  • Hydrose S; Qatar University Biomedical Research Center, Qatar University, Doha, Qatar.
  • Fernandes Q; Translational Research Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar.
  • Ansari AW; Dermatology Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar.
  • Sahir F; Translational Cancer Research Facility, National Center for Cancer Care and Research/ Translational Research Institute, Hamad Medical Corporation, Doha, Qatar.
  • Al-Zaidan L; National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.
  • Jalis M; Qatar University Biomedical Research Center, Qatar University, Doha, Qatar.
  • Ghoul M; Translational Cancer Research Facility, National Center for Cancer Care and Research/ Translational Research Institute, Hamad Medical Corporation, Doha, Qatar.
  • Allahverdi N; National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.
  • Al Homsi MU; Translational Cancer Research Facility, National Center for Cancer Care and Research/ Translational Research Institute, Hamad Medical Corporation, Doha, Qatar.
  • Uddin S; College of Medicine, Qatar University, Doha, Qatar.
  • Jeremijenko AM; Translational Research Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar.
  • Nimir M; Dermatology Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar.
  • Abu-Raddad LJ; Translational Research Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar.
  • Abid FB; Translational Cancer Research Facility, National Center for Cancer Care and Research/ Translational Research Institute, Hamad Medical Corporation, Doha, Qatar.
  • Zaqout A; National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.
  • Alfheid SR; Translational Cancer Research Facility, National Center for Cancer Care and Research/ Translational Research Institute, Hamad Medical Corporation, Doha, Qatar.
  • Saqr HMH; National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.
  • Omrani AS; Translational Cancer Research Facility, National Center for Cancer Care and Research/ Translational Research Institute, Hamad Medical Corporation, Doha, Qatar.
  • Hssain AA; National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.
  • Al Maslamani M; Translational Cancer Research Facility, National Center for Cancer Care and Research/ Translational Research Institute, Hamad Medical Corporation, Doha, Qatar.
  • Yassine HM; National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.
  • Dermime S; National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.
Front Immunol ; 14: 1061255, 2023.
Article en En | MEDLINE | ID: mdl-36817441
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 4_TD Problema de salud: 4_pneumonia Asunto principal: Inmunoterapia Adoptiva / COVID-19 Tipo de estudio: Guideline Límite: Humans Idioma: En Revista: Front Immunol Año: 2023 Tipo del documento: Article País de afiliación: Qatar
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 4_TD Problema de salud: 4_pneumonia Asunto principal: Inmunoterapia Adoptiva / COVID-19 Tipo de estudio: Guideline Límite: Humans Idioma: En Revista: Front Immunol Año: 2023 Tipo del documento: Article País de afiliación: Qatar